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Research Ethics Committees in Africa: 
Building Capacity
Solomon Benatar
In response to the case study by Kass et al. on research ethics 
committees (RECs) in Africa [1], the following additional 
information is provided about capacity building for research 
ethics in South Africa.
South Africa has two programs funded by the Fogarty 
International Center: the International Research Ethics 
Network for Southern Africa (IRENSA; see http:⁄⁄www.irensa.
org) based in Cape Town and the South African Research 
Ethics Training Initiative (SARETI; see http:⁄⁄shsph.up.ac.
za/sareti/sareti.htm) that allies the Universities of Pretoria and 
KwaZulu-Natal. Each of these programs has a different focus 
and both are making highly valued contributions to capacity 
building in international research ethics in Southern Africa. 
The goal of the IRENSA diploma program is to develop 
and nourish sustainable multidisciplinary expertise in 
international research ethics and bioethics in southern 
Africa. It prepares mid-career health and allied professionals 
from South Africa and other developing nations in Africa 
to assume positions of leadership in research ethics in their 
home institutions. This program is unique on the African 
continent in focusing exclusively on training mid-career 
professionals (who cannot take the time or leave to undertake 
full-time graduate work), in three intensive two-week modules 
spread throughout one year, with assignments carried out at 
their home institutions. 
In four years IRENSA trained 49 mid-career professionals 
(17 men, 32 women, 20 white, 29 black) drawn from 20 
institutions in South Africa and from 11 institutions in eight 
other low-income African countries. Sixteen students serve as 
chairs, deputy chairs, or secretaries of RECs. Students reﬂ  ect 
professional training in many disciplines, including science, 
medicine, nursing, social sciences, law, and pharmacology. 
Eighteen students hold doctoral degrees and represent a 
broad spectrum of health organizations. In addition, our 
annual two-day seminars in research ethics have reached over 
400 attendees. 
SARETI’s goal is to build capacity for ethical review of 
health research and strengthen Africa’s institutional training 
capacity necessary to achieve and sustain this aim. It offers 
a multidisciplinary, modular master’s degree program with 
funding for nine trainees over four years, an advanced, 
non-degree program resulting in a certiﬁ  cate with funding 
for 16 trainees, and a training program for 40 ethics review 
committee members. In 2003 SARETI co-hosted, with 
the HIV/AIDS Vaccines Ethics Group, a two-day training 
workshop for over 40 members of South African RECs, and 
in 2004 it offered a three-week Ethics Review Committee 
Training Program sponsorship to nine South African 
applicants. 
A spin-off of these educational programs has been the 
formation of a network of Chairs of South African Human 
Health Research Ethics Committees. This has signiﬁ  cantly 
improved liaison across the country, reduced the potential 
for shopping around by researchers, and has enhanced the 
stringency with which protocols are reviewed. A newsletter 
from Stellenbosch University on research ethics activities in 
the country draws attention to current debates and events 
and facilitates networking [2]. The recent stand taken by 
the chairpersons of RECS in South Africa not to permit 
studies that do not provide insurance cover for research-
related injuries is one example of how improved knowledge 
and coordination in South African RECs are making such a 
contribution [3].  
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Research Ethics Committees in Africa: Authors’ Reply
We thank Dr. Benatar [1] for pointing out that South Africa 
has two Fogarty-funded bioethics training programs: one 
that focuses primarily on providing short-term training 
to mid-career professionals from Southern Africa; and 
another that provides modular training in research ethics to 
professionals from the African continent. In addition, there 
are now several other Fogarty-funded training programs that 
either target African professionals exclusively or include 
African professionals, among others, in their programs 
(see http:⁄⁄www.ﬁ  c.nih.gov/programs/training_grants/
bioethics/index.htm). All of these programs share the goal 
of increasing professional capacity in bioethics and research 
ethics on the African continent. 
Our own paper demonstrated that training even a small 
number of individuals can make a difference in changing 
policy and practice regarding research ethics in several 
institutions; that so many training efforts are now ongoing is a 
major step forward. Again, having more people teaching and 
discussing research ethics and starting and stafﬁ  ng research 
ethics committees will never itself guarantee that research 
with humans is more ethical, but it seems to be a critical 
ﬁ  rst step. Capacity development for Africa still remains a 
challenge and worthy of increasing investments in global 
health.  
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World Social Health Insurance: 
Strengthening Health Systems 
in Low-Income Countries
Wim Van Damme
The paper by Ooms et al. [1] is very timely and stimulating. 
It launches the debate on how to ﬁ  nance globally the right to 
health care in low-income countries. This is a most welcome 
step, going beyond the usual aspirational rhetoric. I would 
like to contribute to the development of this idea.
First: the name. I fear that “World Health Insurance” 
may create confusion. Health insurance can be a pure risk-
sharing mechanism without built-in solidarity between rich 
and poor, healthy and less healthy, or between old and 
young. But the concept of social health insurance—as the 
statutory health insurance systems in much of continental 
Europe are usually referred to—is intrinsically based 
on such solidarity, which certainly is one of the values 
underpinning Ooms’ proposal. I therefore propose the 
name “World Social Health Insurance.”
Second: the contribution by low-income countries. Ooms et 
al. propose 15% of government budget as a fair contribution, 
the so-called Abuja target. I fear, however, that this target 
does not create the right incentive for governments in low-
income countries, many of whom are reluctant or unable 
to tax their citizens, even the richer ones, and fail to create 
a decent tax basis. Consequently, some governments have 
extremely lean budgets, even below 20% of gross domestic 
product (GDP) [2], while the World Bank estimates that at 
least some 30% of GDP is needed to sustain a well-functioning 
state. I therefore think that calculating the contribution of 
low-income countries to their countries’ health system as 
4% or 5% of GDP would constitute a fairer burden sharing 
mechanism.
Third: the contribution of high-income countries. Ooms 
et al. propose that rich countries adopt a burden sharing 
similar to their contribution to World Bank’s IDA 14 (the 
14th replenishment of the International Development 
Association). This normalizes the low commitment of 
donors such as the United States, contributing in absolute 
terms hardly more than the United Kingdom or Japan, 
while its total GDP is much larger. I therefore think that for 
high-income countries, a contribution linked to total GDP 
would be fairer: e.g., 0.15%, which would be a bit more 
than one-ﬁ  fth of the 0.7% target that most OECD countries 
have committed to as total overseas development assistance. 
Alternatively, and more in line with the concept of social 
health insurance, high-income countries could dedicate a 
share of domestic health expenditure (e.g., 1%) to world 
social health insurance. With total health expenditure in the 
United States now reaching US$2,000 billion [3], this modest 
1% would already come close to the total needs as estimated 
by Ooms.
Lastly: operationalization. How to operationalize the 
massive scale-up of services proposed, given present human 
resource constraints and institutional capacities, is still a huge 
challenge. Whether it is best to take inspiration from the 
experience with rounds of competitive proposals, followed by 
performance-related disbursement, as the Global Fund uses, 
or whether the proposal of the Global Alliance for Vaccines 
and Immunisation (GAVI) to link disbursement to strategic 
government plans and sector-wide approaches would be more 
successful, remains to be explored.
We sincerely hope that the idea launched by Ooms 
et al. catches on, so that health services in low-income 
countries can rapidly expand. This can be seen, as Garrett 
convincingly argues [4], as an expression of a moral duty, 
as a form of public diplomacy, or as an investment in self-
protection. Whatever the drive, there are enough reasons 
to start preparing it backed by long-term reliable funding, 
fairly shared between all stakeholders, according to their 
purchasing power.  
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Circumcision for HIV Prevention: 
Failure to Fully Account for Behavioral 
Risk Compensation
Seth Kalichman, Lisa Eaton, Steven Pinkerton
Three randomized controlled trials (RCTs) of male 
circumcision (MC) have been halted when interim analyses 
showed signiﬁ  cant reductions in HIV infection among men 
who received this intervention [1–3]. Modeling suggests 
that increased MC coverage in southern Africa could 
prevent as many as 2 million HIV infections over ten years 
[4]. Moreover, the cost-effectiveness analysis by Kahn et 
al. recently published in PLoS Medicine indicates that MC 
could be cost-saving [5]. However, the protection of MC 
may be partially offset by increased HIV risk behavior, or 
“risk compensation,” especially reduction in condom use 
or increases in numbers of sex partners. Risk compensation 
occurs when individuals adjust their behavior in response 
to perceived changes in their vulnerability to a disease [6]. 
Risk compensation may be especially important for MC 
because avoiding the sexual dissatisfactions of condom use 
and the desire to have more sex partners are likely to be 
signiﬁ  cant motivations for men to seek circumcision [7]. In 
South Africa, 73% of men between the ages of 15 and 24 
report using condoms during the last time they had sex [8]. 
It is difﬁ  cult to imagine a convincing public health message 
that effectively inﬂ  uences men to undergo circumcision and 
continue to consistently use condoms.
Circumcised men in the ANRS 1265 trial reported 18% 
more sexual contacts at follow-up than did uncircumcised 
men, but no other sexual behavior differences were obtained 
[1]. However, for ethical reasons all men in MC RCTs 
receive ongoing risk-reduction counseling and free condoms, 
which reduces the utility of these trials for estimating the 
potential behavioral impact of MC when implemented 
in a natural setting. One model of the potential impact 
of MC did not take into account risk compensation [4], 
but noted that “increases in risk-taking behaviour among 
circumcised men could reduce the beneﬁ  t of MC.” Based 
on the 18% difference in sexual contacts for circumcised 
and uncircumcised men in the ANRS 1265 trial and the 
assumption that “risk compensation might be higher in a 
nonresearch program scale-up,” Kahn et al. [5] adjusted the 
60% effectiveness estimate obtained in this RCT downward to 
50% to reﬂ  ect a 25% increase in sexual risk behaviors among 
circumcised men. Although Kahn et al.’s model explicitly 
incorporated the increased risk of HIV acquisition associated 
with risk compensation, it did not consider the impact of risk 
compensation on the HIV transmission risk of HIV-infected 
circumcised men, or on circumcised men’s risk for non-HIV 
sexually transmitted infections (STIs).
There is no evidence that circumcision increases or 
decreases the risk of HIV transmission by HIV-infected men. 
However, risk compensation by HIV-infected circumcised 
men will substantially increase the risk of transmission to 
their sex partners. This suggests that, in the short term at 
least, circumcision would reduce the incidence of HIV among 
men, but increase the incidence among women, translating to 
increased prevalence among women, which in turn translates 
to greater risk to men. Epidemiological models of MC should 
take this dynamic into account.
Countless studies have shown that ulcerative and non-
ulcerative STIs account for at least some of the rapid increases 
in HIV transmission in southern Africa [9]. Non-HIV STIs are 
associated with a 2- to 5-fold increase in HIV transmission risk 
in countries with low and high rates of MC [9]. In areas with 
prevalent STIs, the relative increase in men’s STI-associated 
HIV risk can be as high as 60% to 340% [10]. Circumcision 
likely reduces the risk of acquiring a non-HIV STI and may 
be partially responsible for the decreased HIV risk observed 
in circumcision RCTs [1]. Nevertheless, the failure of models 
to account for increased STI risk due to risk compensation 
likely inﬂ  ates estimates of averted HIV infections. Estimates 
of HIV risks resulting from increased exposure to STIs that 
coincide with reductions in condom use have been included 
in previous models of the cost-effectiveness of HIV prevention 
interventions [11] and should be included in MC models.  
Seth Kalichman (seth.kalichman@uconn.edu)
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Circumcision for HIV Prevention: Authors’ Reply
The issues regarding risk compensation raised by Kalichman 
et al. [1] are cogent for reﬁ  ning modeled estimates of the 
impact of male circumcision (MC). Even more important is to 
empirically monitor risk compensation during the scale-up of 
male circumcision.
As Kalichman et al. note, we included in our modeling of 
MC impact a risk compensation level for men susceptible to 
HIV above that observed in the Orange Farm trial. 
However, we did not incorporate risk compensation among 
the HIV infected, an adjustment which would have lessened 
the estimated beneﬁ  ts of male circumcision. These two biases 
are offsetting. Another conservative bias in our analysis is 
that we used the per-randomization protective effect of 0.60, 
rather than the per-clinical protocol protective effect of 0.70. 
Arguably, effectiveness in practice is better captured by the 
latter, and this would increase the estimated beneﬁ  ts of male 
circumcision.
The inclusion of the effects of non-HIV sexually 
transmitted infections (STIs) as risk co-factors would add a 
useful dimension to our analysis. The net effect could be to 
decrease or increase MC impact. As Kalichman et al. note, 
increased STIs associated with risk compensation in newly 
circumcised HIV-infected men would likely lessen MC impact. 
However, in a concentrated epidemic setting where STIs play 
a greater role in HIV transmission than in South Africa, the 
STI-reducing effects of MC in HIV-susceptible men could 
further increase the beneﬁ  ts of MC in preventing HIV.
Regarding the magnitude of risk compensation, we are 
encouraged by recent data suggesting that MC does not 
increase risky behavior, and may lead to a transient decrease 
[2]. However, we, like Kalichman et al. and others, are eager 
to see the favorable experience in clinical trials carried 
over to routine and widely operating programs. Thus, the 
current efforts to plan MC scale-up emphasize the need for 
an MC procedure that incorporates effective risk reduction 
counseling. In the context of a medicalized adult male 
circumcision model, and a clear public health message, risk 
compensation can be minimized. Thus, a great value of 
MC scale-up is the opportunity to directly deliver a strong 
behavioral prevention message. A similar risk reduction 
message has worked well with antiretroviral therapy in Africa 
[3]. 
The ultimate and critical test is monitoring risk behaviors 
in communities where MC is scaled up. If risk compensation 
is higher than expected, redoubled risk reduction methods 
will be imperative.  
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Counterfeit Artemisinin Derivatives 
and Africa: Update from Authors
Paul N. Newton, Michael D. Green, Facundo Fernandez
Since the publication of our article on counterfeit artesunate 
in June 2006 [1], further information has become available 
which we would like to report, as it has public health 
signiﬁ  cance. An additional two counterfeit artesunate “types” 
with distinguishing features of the packaging have been found 
in mainland Southeast Asia, bringing the number of physical 
types to at least 14. For details see “Fake Artesunate Warning 
Sheet Number 5a” [2], an update (dated August 2006) to that 
published as supplementary material to the above paper.
In addition, we would like to bring readers’ attention 
to the newspaper reports of counterfeit artesunate and 
dihydroartemisinin seized from ladies’ handbags at Lagos 
airport [3].
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Children Born to HIV-Infected Mothers 
in Côte d’Ivoire: Methodological 
Clariﬁ  cations Needed
Moussa Sarr
In their recently published paper, Becquet et al. [1] found 
that the 2-years rates of adverse health outcomes were similar 
among short-term breast-fed and formula-fed children. 
Mortality rates also did not differ signiﬁ  cantly between these 
two groups and, after adjustment for pediatric HIV status, 
were similar to those observed among long-term breast-fed 
children. These results conﬁ  rm the ﬁ  ndings of two previous 
trials in Kenya [2] and in Botswana [3], highlighting the fact 
that with adequate support, alternatives to prolonged breast-
feeding can be safe options for mothers to prevent mother-
to-child transmission of HIV in African settings. HIV-infected 
mothers who opt for alternatives to breast-feeding to protect 
their children from HIV infection should be provided the 
necessary support to make their choice feasible.
There are, however, some methodological clariﬁ  cations 
that need to be made regarding the incidence rates of 
diarrhea, acute respiratory infection, and malnutrition. It 
was not clear if all repeated episodes of diarrhea and acute 
respiratory infection were taken into account to compute 
the incidence rates. A number of epidemiologists have also 
been advocating the use of longitudinal prevalence instead 
of incidence for the longitudinal measure of morbidity 
associated with childhood diarrhea [4]. The longitudinal 
prevalence is deﬁ  ned by the number of days of diarrhea 
divided by the total number of days of observation for each 
child. Longitudinal prevalence was found to be a better 
predictor of long-term health outcome in relationship to 
childhood diarrhea [4].  
Moussa Sarr (moussasarr@westat.com)
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Rockville, Maryland, United States of America
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Placental Malaria: Hypertension, 
VEGF, and Prolactin
Roy Douglas Pearson
The ﬁ  ndings by Muehlenbachs et al. [1] that placental 
malaria (PM) is associated with hypertension in ﬁ  rst-time 
mothers aged 18  –20 years is signiﬁ  cant, and not to be 
explained at this time of writing. The authors also provide 
data suggesting that the maternal–fetal conﬂ  ict, during 
chronic PM and hypertension in ﬁ  rst-time mothers, involves 
the VEGF pathway. 
Previously [2–5], I have posited that prolactin might have 
a role in PM and these new ﬁ  ndings might provide further 
indirect evidence for such a role. It should be remembered 
that there is an extensive and decades-old literature (see 
Horrobin’s chapter 23 in [6]) on the role of prolactin in 
hypertension; and more speciﬁ  cally, the relationship between 
prolactin and pregnancy-related hypertension [7,8]. 
Regarding the VEGF pathway, Malaguarnera et al. 
[9] have recently shown that prolactin induces VEGF 
production in human macrophages. It is conceivable that 
hyperprolactinemia (pituitary and/or placental) could up-
regulate placental macrophage production of VEGF.
Space does not permit a discussion of the well known 
fact of increased pregnancy-related prolactin in ﬁ  rst-time 
mothers, but this has been noted elsewhere [2] concerning 
maternal malaria.
Although there has been controversy of late [2,10], 
regarding my “prolactin hypothesis” in maternal malaria, 
it is time deﬁ  nitive experiments be conducted to ascertain 
if prolactin is playing a role in PM, and in other infectious 
diseases as well.  
Roy Douglas Pearson (r.pearson@utoronto.ca)
University of Toronto, Gerstein Science Information Centre
Toronto, Ontario, Canada
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Pollution and Tuberculosis: 
Outdoor Sources
Aaron Cohen, Sumi Mehta
The meta-analysis by Lin and colleagues [1] is important for 
two reasons. It evaluates the evidence concerning exposure to 
combustion-derived air pollution and tuberculosis (TB), and 
it quantiﬁ  es the risk of TB associated with three important 
sources of exposure: tobacco smoking, environmental 
tobacco smoke, and indoor burning of solid fuels. Their 
analysis invites speculation about the possible role of another 
combustion source: outdoor urban air pollution, a growing 
problem in developing countries where the burden of disease 
from TB is greatest. 
Combustion-source air pollution affects resistance 
to infection via effects on airway resistance, epithelial 
permeability, and macrophage function [2]. Studies suggest 
a speciﬁ  c role for ﬁ  ne particles less than 2.5 micrometers 
in diameter (PM2.5) [3]. PM-associated transition metals, 
e.g., iron, are thought to produce oxidative stress in the 
lung, hypothesized to be a common factor in a range of 
adverse effects [4], and have been associated with altered 
host defenses in rats [5]. As Lin notes, the amount of iron in 
the lung has also been hypothesized to adversely affect the 
progression of TB [6,7].
Air pollution from outdoor sources, such as motor vehicles, 
industry, and neighborhood-level solid waste burning, is 
associated with increased morbidity and mortality from 
respiratory infections in children and adults [8,9]. Only one 
study of outdoor air pollution and tuberculosis has been 
reported in the peer-reviewed literature to date [10], but 
one might speculate that outdoor air pollution would have a 
similar impact on TB infection and/or progression of disease 
via the mechanisms described above. 
People in urban areas of developing countries are 
exposed to the highest levels of outdoor air pollution in 
the world, which each year impose an estimated burden 
of hundreds of thousands of deaths and millions of years 
of healthy life lost from cardiovascular disease, selected 
respiratory diseases, and lung cancer [11]. TB was not 
considered due to lack of evidence, so these estimates 
assume that outdoor air pollution plays no role. If, however, 
air pollution exposure increases the risk of infection, illness, 
or death from TB, then the attributable burden of disease 
would be even greater. 
Environmental policy in developing countries should be 
informed by the best and most complete information on the 
health effects of air pollution. New research efforts should 
address health outcomes of regional relevance, such as TB 
and childhood respiratory illness. Since TB is endemic in 
many developing countries, even a small increase in risk 
could translate into a large attributable burden. Research on 
outdoor air pollution and TB seems warranted.  
Aaron Cohen (acohen@healtheffects.org) 
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Training and Experience of Peer 
Reviewers: An Additional Variable 
to Consider
Erik Kulstad
I read with interest your article [1] on peer reviewers’ 
review quality and the relationship to previous training and 
experience, particularly the fact that your study found no 
easily identiﬁ  able types of formal training or experience that 
predict reviewer performance. As you conclude, without a 
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better understanding of the skills in scientiﬁ  c peer review, 
journals and editors will have difﬁ  culty in systematically 
improving their selection of reviewers. 
I wonder if an additional variable not examined in your 
study may prove potentially predictive of performance, 
namely the time committed by a reviewer to the review 
process in general, or a given review in particular. This 
data point could easily be provided by a reviewer, albeit 
with the caution that a self-reported number will have 
some subjectivity that is immeasurable. This variable could 
be speciﬁ  ed either as the a priori time that an individual 
reviewer is willing and/or able to put towards completing a 
review or a self-reported time spent in actually completing a 
review. Either a simple dichotomized variable, say, less than 
four hours or greater than four hours spent on a review, or a 
measurement on a continuous scale, might be revealing. 
Perhaps if the self-reported time commitment to a given 
manuscript review is found to correlate with quality of the 
review in a univariable or multivariable model, an additional 
criteria for selecting reviewers can be based on this question. 
A positive correlation might also explain the paradoxical 
ﬁ  ndings of worse performance when being a peer reviewer 
for another journal or when serving on an institutional review 
board. Increased availability of time to commit to the process 
may also explain the ﬁ  ndings of improved review quality 
with younger training status, if one presumes that free time 
diminishes with age!  
Erik Kulstad (ekulst@yahoo.com)
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Training and Experience of Peer 
Reviewers: Is Being a “Good Reviewer” 
a Persistent Quality?
Ignacio García-Doval
After reading your interesting paper [1], I think that all 
editors will feel a bit disappointed that there are no magic 
answers to their practical question: who will be a good 
reviewer for this paper?
So, they will probably stick to the old practice: try to get a 
good group of reviewers and ask them to do it. However, this 
way of working is based on the assumption that being a good 
reviewer is a long-lasting quality, so that doing a good review 
predicts that the next review will also be good.
I could not ﬁ  nd a clear answer to that question in this 
paper. I think that with their dataset the authors can probably 
provide us with an answer that will reassure editors on their 
decision to stick to the group of reviewers that have produced 
good reviews in the past.
Would they be so kind?  
Ignacio García-Doval (ignacio.garcia.doval@sergas.es)
Complexo Hospitalario de Pontevedra 
Pontevedra, Spain
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Training and Experience of Peer Reviewers: 
Authors’ Reply
Dr. Ignacio García-Doval [1] raises an interesting question—if 
a reviewer initially proves themselves of high quality at a 
particular journal, can we count on them to continue in this 
vein?
We have not examined this as thoroughly as the predictive 
factors, but we have found that good reviewers, on 
average, continue to produce good reviews for many years. 
However, their performance is not so consistent that one 
can completely cease monitoring them, because a modest 
proportion will deteriorate, presumably due to changes in 
their personal or professional lives. We have had reviewers 
who were reliably good for many years, but whose scores then 
steadily deteriorated until we were forced to retire them.
This reinforces our recommendation that all but the 
most resource-poor journals should routinely rate reviewers, 
something not hard to do in this era of ubiquitous computer 
databases. We recommend a look at those ratings about once 
a year, and feedback of some kind to those doing poorly. 
Another beneﬁ  t is that this also identiﬁ  es the high performers, 
who can then be rewarded in some way for their donated labor 
(a note of thanks, inexpensive objects with your journal logo, 
free continuing medical education for their review time, etc.). 
Consistent very high performers also serve as a good source for 
future editorial board appointments.  
Michael Callaham (mlc@medicine.ucsf.edu)
University of California San Francisco
San Francisco, California, United States of America
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